

Integrated Filing (Finance) Ind AS

Orchid Pharma Limited

General Information

Scrip code*	524372	
NSE Symbol*	ORCHPHARMA	
MSEI Symbol*	NOTLISTED	
ISIN*	INE191A01027	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Date of board meeting when results were approved	12-08-2025	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	05-08-2025	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Quarterly	
Reporting Quarter	First quarter	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Unaudited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended		
Segment Reporting	Single segment	
Description of single segment	Pharmaceutical	
Start date of board meeting	12-08-2025	
Start time of board meeting	12:00:00	
End date of board meeting	12-08-2025	
End time of board meeting	15:30:00	
Whether cash flow statement is applicable on company		
Type of cash flow statement		
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	true	
No. of times funds raised during the quarter	1	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	false	Textual Information(1)

Text Block

Textual Information(1)	Not Applicable as the Company has not defaulted on Loans and Debt Securities during the reporting period. Also, the Company has not raised funds during the quarter but due to the mandatory requirement in technical point of this utility at Row No. 42 of this page is selected as 1.
---------------------------	---

Financial Results - Ind-AS

Amount in (Lakhs)

Particulars	3 months/ 6 months ended (dd-mm- yyyy)	Year to date figures for current period ended (dd-mm- yyyy)
Date of start of reporting period	01-04- 2025	01-04- 2025
Date of end of reporting period	30-06- 2025	30-06- 2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
Blue color marked fields are non-mandatory. For Consolidated Part Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1 Income		
Revenue from operations	17,292.88	17,292.88
Other income	1,593.04	1,593.04
Total income	18,885.92	18,885.92
2 Expenses		
(a) Cost of materials consumed	11,015.74	11,015.74
(b) Purchases of stock-in-trade	78.79	78.79
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,207.99)	(1,207.99)
(d) Employee benefit expense	2,161.29	2,161.29
(e) Finance costs	325.75	325.75
(f) Depreciation, depletion and amortisation expense	865.41	865.41
(g) Other Expenses		
1 Other expenses	3,827.19	3,827.19
Total other expenses	3,827.19	3,827.19
Total expenses	17,066.18	17,066.18
Total profit before exceptional items and tax	1,819.74	1,819.74
4 Exceptional items	0.00	0.00
5 Total profit before tax	1,819.74	1,819.74
6 Tax expense		
7 Current tax	0.00	0.00
8 Deferred tax	0.00	0.00
9 Total tax expenses	0.00	0.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00
11 Net Profit Loss for the period from continuing operations	1,819.74	1,819.74
12 Profit (loss) from discontinued operations before tax	0.00	0.00
13 Tax expense of discontinued operations	0.00	0.00

14	Net profit (loss) from discontinued operation after tax	0.00	0.00
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00
16	Total profit (loss) for period	1,819.74	1,819.74
17	Other comprehensive income net of taxes	(15.48)	(15.48)
18	Total Comprehensive Income for the period	1,804.26	1,804.26
19	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	Details of equity share capital		
	Paid-up equity share capital	5,071.91	5,071.91
	Face value of equity share capital	10.00	10.00
22	Reserves excluding revaluation reserve		
23	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	3.59	3.59
	Diluted earnings (loss) per share from continuing operations	3.59	3.59
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0.00	0.00
	Diluted earnings (loss) per share from discontinued operations	0.00	0.00
iii	Earnings per equity share (for continuing and discontinued operations)		
	Basic earnings (loss) per share from continuing and discontinued operations	3.59	3.59
	Diluted earnings (loss) per share from continuing and discontinued operations	3.59	3.59
24	Debt equity ratio		
25	Debt service coverage ratio		
26	Interest service coverage ratio		
27	Remarks for debt equity ratio		
28	Remarks for debt service coverage ratio		
29	Remarks for interest service coverage ratio		
30	Disclosure of notes on financial results	Textual Information(1)	

Text Block

Textual Information(1)	<p>1. The above results for the quarter and year ended June 30 , 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on August 12, 2025. The statutory auditors of the company have expressed an unmodified opinion on the audited Standalone results and a modified opinion on the audit of the Consolidated results.</p> <p>2.The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act, 2013, read with the Companies Indian Accounting Standards Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable.</p> <p>3. 99,02,705 fully paid up Equity Shares of face value INR10 each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement ,QIP, whereby proceeds of Rs.39180 Lakhs ,Net of Share issue expenses, was raised.</p> <p>As on June 30, 2025, the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below :</p> <p>Statement of QIP Net Funds raised and utilisation</p> <table border="1"><thead><tr><th>Particulars</th><th>Amount as stated in the Offer Document upto June 30, 2025</th><th>Total amount utilised upto June 30, 2025</th><th>Balance amount as on June 30, 2025</th><th>Remarks</th></tr></thead><tbody><tr><td>Rs. In Lakhs</td><td>Rs. In Lakhs</td><td>Rs. In Lakhs</td><td>Rs. In Lakhs</td><td></td></tr><tr><td>1. Investment in OBPL, subsidiary, for setting up Jammu Manufacturing Facility</td><td>9000</td><td>6461</td><td>2539</td><td></td></tr><tr><td>2. Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the company</td><td>14100</td><td>14100</td><td>-</td><td></td></tr><tr><td>3. Funding capital expenditure requirements for setting up a new block at the API facility of the Company in Alathur, Tamil Nadu</td><td>9982</td><td>36</td><td>9946</td><td></td></tr><tr><td>4. General corporate purposes</td><td>6098</td><td>6372</td><td>0</td><td></td></tr><tr><td>Total</td><td>39180</td><td>26969</td><td>12485</td><td></td></tr></tbody></table> <p>As per the QIP offer Document the amount allocated for General Corporate Purpose, GCP, was Rs. 6098 Lakh which was based on the proposed net proceeds after issue expenses</p>	Particulars	Amount as stated in the Offer Document upto June 30, 2025	Total amount utilised upto June 30, 2025	Balance amount as on June 30, 2025	Remarks	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs		1. Investment in OBPL, subsidiary, for setting up Jammu Manufacturing Facility	9000	6461	2539		2. Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the company	14100	14100	-		3. Funding capital expenditure requirements for setting up a new block at the API facility of the Company in Alathur, Tamil Nadu	9982	36	9946		4. General corporate purposes	6098	6372	0		Total	39180	26969	12485	
Particulars	Amount as stated in the Offer Document upto June 30, 2025	Total amount utilised upto June 30, 2025	Balance amount as on June 30, 2025	Remarks																																
Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs																																	
1. Investment in OBPL, subsidiary, for setting up Jammu Manufacturing Facility	9000	6461	2539																																	
2. Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the company	14100	14100	-																																	
3. Funding capital expenditure requirements for setting up a new block at the API facility of the Company in Alathur, Tamil Nadu	9982	36	9946																																	
4. General corporate purposes	6098	6372	0																																	
Total	39180	26969	12485																																	

being Rs.39180 Lakh. However, net proceeds transferred to Monitoring Account was Rs. 39454 Lakh as against the proposed net Proceeds of Rs. 39180 Lakh, therefore the Surplus amount of Rs. 274 Lakh has been included in the GCP balance as on June 30, 2025.

Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits.

4. The operations of the Company falls under a single operating segment i.e., Pharmaceuticals in accordance with Ind AS 108, Operating Segments, and hence no reporting as per Ind AS 108 is applicable.

5. The figures for the quarters ended 31 March, 2025 represents the balancing figures between audited results for the year ended March 31, 2025 and the published year to date figures up to the third quarter of the relevant year.

6. The Company has submitted a petition with the Honourable National Company Law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited, the Amalgamating Company, with the Company in compliance with Section 230 to 232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation Letter from the BSE Limited and National Stock Exchange of India Limited, stock exchanges, giving No objection to the said amalgamation. The Honourable NCLT vide its order dated 29th April, 2025 , inter alia, issuing directions for convening meetings of equity shareholders of the Company and unsecured creditors of both Companies and dispensed with the meetings of equity shareholders of the Amalgamating Company and secured creditors of both the Companies, considering their respective consents to the Scheme already submitted before the Honourable NCLT. Subsequently, the requisite approvals of the concerned shareholders and creditors, as directed, have duly been secured. Further the companies submitted the joint company petition seeking approval on the scheme of Amalgamation, pursuant to which the Honourable NCLT admitted the petition for its consideration and sanction.

7. Figures of the previous period have been regrouped or reclassified or restated wherever considered necessary.

Other Comprehensive Income

Amount in (Lakhs)

Particulars	3 months/ 6 months ended (dd-mm- yyyy)	Year to date figures for current period ended (dd-mm- yyyy)
Date of start of reporting period	01-04- 2025	01-04- 2025
Date of end of reporting period	30-06- 2025	30-06- 2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
Other comprehensive income [Abstract]		
1 Amount of items that will not be reclassified to profit and loss		
1 Items that will not be reclassified to profit and loss	(15.48)	(15.48)
Total Amount of items that will not be reclassified to profit and loss	(15.48)	(15.48)
2 Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
3 Amount of items that will be reclassified to profit and loss		
Total Amount of items that will be reclassified to profit and loss		
4 Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5 Total Other comprehensive income	(15.48)	(15.48)

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising	QIP
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	27-06-2023
Amount Raised	40,000.00
Report filed for Quarter ended	30-06-2025
Monitoring Agency	true
Monitoring Agency Name, if applicable	Care Ratings Limited
Is there a Deviation / Variation in use of funds raised	false
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	
Comments of the Audit Committee after review	<p>Remark 1 Delay in implementation of the object(s) w.r.t the object-Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu but the extent of delay is not ascertainable. Comment Alathur project is for further processing of proposed 7ACA into intermediate goods or downstream products from Jammu Project. The Land acquisition for setting up 7ACA project at Jammu is delayed. Consequently, there is delay in setting up of API Facility at Alathur. Hence the major amount remained unutilised.</p> <p>Remark 2 Delay in implementation of the object(s) w.r.t the object-Investment in</p>

OBPL for setting up Jammu Manufacturing Facility but the extent of delay is not ascertainable. Comment The Land of around 203.8 Kanal (25.475 acres) at Jammu had been identified, out of which registration of 158.30 Kanal (19.79 acres) of land has completed and registration of the remaining land parcel is expect to be completed before October 2025. Bhoomi Pooja for the project was successfully performed on September 07, 2024. Construction of boundary and building work had been already started. Purchase orders for major equipments have also been placed and delivery of equipments at site will start shortly. The Land acquisition task has been given to Land aggregator who is getting the land from various farmers. Getting the agreement signed from various farmers has taken time. Further for this land Change of Land Use (CLU) or registration was required. This has led to delay in acquiring land.

Comments of the auditors, if any

Objects for which funds have been raised and where there has been a deviation, in the following table:

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Investment in Orchid Bio Pharma Limited for setting up Manufacturing Facility in Jammu	Not Applicable	9,000.00	0.00	6,461.00	0.00	Textual Information(1)
2	Repayment or prepayment, in full or in part, of certain outstanding borrowings availed by our Company	Not Applicable	14,100.00	0.00	14,100.00	0.00	
3	Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu	Not Applicable	9,982.00	0.00	36.00	0.00	
4	General Corporate Purposes	Not Applicable	6,098.00	0.00	6,372.00	0.00	Textual Information(2)

Text Block

Textual Information(1)	Monitoring Agency in its Report dated August 04, 2025 had comments that The company has transferred Rs 20.45 crores from MA account to CC account as reimbursement of investment already made in OBPL from its own sources.
Textual Information(2)	As per the QIP offer document the amount allocated for GCP was Rs.6098 Lakhs which was on the basis of proposed net proceeds after issue expenses, being Rs.39180 Lakhs. However, net Proceeds transferred to Monitoring Account was Rs.39454 Lakhs as against the proposed Net Proceeds of Rs.39180 Lakhs, therefore the GCP was revised to Rs.274 lakhs has been included in the GCP and therefore the GCP balance was revised to Rs.6372 Lakhs.

Signatory Details

Name of signatory	Kapil Dayya
Designation of person	Company Secretary and Compliance Officer
Place	Gurugram
Date	12-08-2025